Oncology · Phase II

Top sponsors

• First People's Hospital 261 programs
• Chinese Academy of 198 programs
• George Institute for 118 programs
• United Therapeutics Europe 112 programs
• Telethon Foundation 91 programs
• Takeda 79 programs
• Regeneron UK 71 programs
• MSD Merck Sharp 63 programs
• Ningbo Cancer Hospital 62 programs
• Anaxis Pharma 57 programs
• AstraZeneca 52 programs
• HOFFMANN-LA ROCHE 50 programs

1. Lynparza film-coated tablets for recurrent ovarian cancer wild t…

   Fondazione Telethon ETS

   recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

   phase 2 · small molecule · active

   1 trial →

2. M22-132

   AbbVie Deutschland GmbH & Co. KG

   B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma

   phase 2 · small molecule · active

   1 trial →

3. M24-147

   AbbVie Deutschland GmbH & Co. KG

   Hepatocellular Carcinoma

   phase 2 · small molecule · active

   1 trial →

4. M24-311

   AbbVie Deutschland GmbH & Co. KG

   Colorectal Cancer

   phase 2 · small molecule · active

   1 trial →

5. M24-533

   AbbVie Deutschland GmbH & Co. KG

   Metastatic Colorectal Cancer

   phase 2 · small molecule · active

   1 trial →

6. M24-633

   AbbVie Deutschland GmbH & Co. KG

   Small Cell Lung Cancer

   phase 2 · small molecule · active

   1 trial →

7. M24-977

   AbbVie Deutschland GmbH & Co. KG

   Adenocarcinoma of the gastroesophageal junction

   phase 2 · small molecule · active

   1 trial →

8. M25-204

   AbbVie Deutschland GmbH & Co. KG

   Urothelial Carcinoma, Metastatic Urothelial Carcinoma

   phase 2 · small molecule · active

   1 trial →

9. M25-709

   AbbVie Deutschland GmbH & Co. KG

   Ovarian Cancer

   phase 2 · small molecule · active

   1 trial →

10. M9140

    Serono Europe Limited

    Solid Tumors

    phase 2 · small molecule · active

    1 trial →

11. M9140

    Merck Sharp and Dohme

    Pancreatic Ductal Adenocarcinoma

    phase 2 · small molecule · active

    1 trial →

12. M9140

    Merck Sharp and Dohme

    Gastric Cancer

    phase 2 · small molecule · active

    1 trial →

13. M9140

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

14. MB-106

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 2 · small molecule · active

    1 trial →

15. MB-huCART19.1

    AXIM BIOTECHNOLOGIES, INC.

    B-cell precursor ALL, B-cell Non Hodgkin Lymphoma

    phase 2 · small molecule · active

    1 trial →

16. MB07133 300mg/m2/day

    LIGAND PHARMACEUTICALS INC

    Hepatocellular Carcinoma

    phase 2 · small molecule · completed

    1 trial →

17. MCLA-128

    Partner Therapeutics Limited

    Solid Tumors

    phase 2 · small molecule · active

    1 trial →

18. MDNA11

    Medicenna Therapeutics

    Advanced Solid Tumor

    phase 2 · small molecule · active

    1 trial →

19. MDNA11-01

    Medicenna Therapeutics

    Advanced Solid Tumors

    phase 2 · small molecule · active

    1 trial →

20. ME-CLN-002

    CASI Pharmaceuticals

    Carcinoid Tumor

    phase 2 · small molecule · completed

    1 trial →

21. MEDI4736

    AstraZeneca

    Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

    phase 2 · small molecule · completed

    1 trial →

22. METFORAL 850 mg compresse rivestite con film

    Fondazione Telethon ETS

    Triple negative breast cancer

    phase 2 · small molecule · active

    1 trial →

23. METFORMIN

    Istituto Gentili S.r.l.

    bone sarcoma

    phase 2 · small molecule · active

    1 trial →

24. MIA2019/CT/258

    The George Institute

    melanoma brain metastases

    phase 2 · small molecule · active

    1 trial →

25. MIBIOTIMI

    The George Institute

    Breast cancer

    phase 2 · other · active

    1 trial →

26. MIE

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 · other · active

    1 trial →

27. MITO 25.1

    Fondazione Telethon ETS

    Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

    phase 2 · small molecule · active

    1 trial →

28. MITO 35a

    Fondazione Telethon ETS

    BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

    phase 2 · small molecule · active

    1 trial →

29. MITO VULVA-01

    Fondazione Telethon ETS

    vulvar cancer

    phase 2 · small molecule · active

    1 trial →

30. MK-1022-010

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 · small molecule · active

    1 trial →

31. MK-1022-011

    Merck Sharp and Dohme

    Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatocellular Carcinoma​

    phase 2 · small molecule · active

    1 trial →

32. MK-1026-003

    Merck Sharp and Dohme

    Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphoma, Marginal zone lymphoma; Follicular lymphoma; Waldenström’s macroglobulinemia

    phase 2 · small molecule · active

    1 trial →

33. MK-1045

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphoblastic Leukemia

    phase 2 · small molecule · active

    1 trial →

34. MK-1084-014

    Merck Sharp and Dohme

    Neoplasm malignant with KRAS G12C mutation

    phase 2 · small molecule · active

    1 trial →

35. MK-1200-002

    Merck Sharp and Dohme

    Advanced solid tumor

    phase 2 · small molecule · active

    1 trial →

36. MK-2140-006

    Merck Sharp and Dohme

    Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome)

    phase 2 · small molecule · active

    1 trial →

37. MK-2140-011

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 · small molecule · active

    1 trial →

38. MK-2400-01A

    Merck Sharp and Dohme

    Metastatic castrate resistant prostate cancer - mCRPC

    phase 2 · small molecule · active

    1 trial →

39. MK-2870-027

    Merck Sharp and Dohme

    Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 2 · other · active

    1 trial →

40. MK-3120

    Merck Sharp and Dohme

    High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

    phase 2 · small molecule · active

    1 trial →

41. MK-3120

    Merck Sharp and Dohme

    Advanced/metastatic solid tumor disease

    phase 2 · small molecule · active

    1 trial →

42. MK-3475-01A

    Merck Sharp and Dohme

    non-small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

43. MK-3475-01B

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 · small molecule · active

    1 trial →

44. MK-3475-01C

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

45. MK-3475-01E

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 · small molecule · active

    1 trial →

46. MK-3475-01F

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 · small molecule · active

    1 trial →

47. MK-3475-01H

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

48. MK-3475-01I

    Merck Sharp and Dohme

    Stage IV Squamous Non-Small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

Frequently asked questions